
Tendon xanthomas are a recognized but underappreciated cause of clinical presentations mimicking inflammatory arthropathies, potentially leading to diagnostic delay and inappropriate immunosuppression. We report a 55-year-old woman presenting with polyarthralgia and multiple painless nodular swellings over the metacarpophalangeal (MCP) joints, metatarsophalangeal (MTP) joints, and Achilles tendons. Inflammatory markers were normal, and rheumatoid factor and anti-cyclic citrullinated peptide antibodies were negative. Bilateral xanthelasma palpebrarum was noted. A nonfasting lipid profile demonstrated marked hypercholesterolemia (total cholesterol 328.68 mg/dL; LDL-C 264.68 mg/dL) and hypertriglyceridemia (249.08 mg/dL). High-resolution ultrasonography demonstrated hypoechoic, nonvascular tendon thickening involving the hands, feet, Achilles tendons, and left quadriceps tendon, without synovitis or communication with the joint space. These findings supported a diagnosis of tendon xanthomatosis associated with definite clinical familial hypercholesterolemia (Dutch Lipid Clinic Network score: 11 points). This case emphasizes the importance of considering metabolic causes of periarticular nodules when clinical and ultrasonographic findings do not support inflammatory arthritis.
Objective. Emerging evidence implicates LL-37 in the underlying mechanisms of autoimmune disorders. This study aimed to determine serum levels of the antimicrobial peptide LL-37 in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and psoriatic arthritis (PsA) and assess their association with disease activity. Methods. A cross-sectional study included three groups of 30 patients each with RA, SLE, and PsA, respectively, and 30 healthy controls. Serum LL-37 levels were measured using an enzyme-linked immunosorbent assay (ELISA). Disease activity indices (Disease Activity Score in 28 joints based on erythrocyte sedimentation rate [DAS28-ESR], Systemic Lupus Erythematosus Disease Activity Index 2000 [SLEDAI-2K], and Disease Activity in Psoriatic Arthritis [DAPSA]) and inflammatory markers (erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) were recorded. Results. Mean serum LL-37 levels were higher in the RA (19.9 ± 16.18), SLE (16.5 ± 11.49), and PsA (16.9 ± 10.4) groups than in controls (3.6 ± 0.95; all p < 0.001). Positive correlations were observed between LL-37 levels and DAS28-ESR (rs = 0.371, p = 0.044), SLEDAI-2K (rs = 0.751, p ≤ 0.001), and DAPSA (rs = 0.564, p ≤ 0.001), with higher LL-37 levels associated with higher disease activity. Conclusion. Serum LL-37 levels were significantly higher in patients with RA, SLE, and PsA than in healthy controls and were positively correlated with measures of disease activity in these inflammatory rheumatic diseases.
Background. Psoriatic arthritis (PsA) is associated with increased cardiovascular risk, but the relationship between serum monocyte chemoattractant protein-1 (MCP-1) and echocardiographic abnormalities remains uncertain. Objective. To compare serum MCP-1 concentrations and echocardiographic findings between patients with PsA and healthy controls and, as an exploratory analysis, to examine associations between MCP-1 and ventricular dysfunction within the PsA group. Materials and methods. In this exploratory cross-sectional case-control study, 38 adults fulfilling the Classification Criteria for Psoriatic Arthritis (CASPAR) and 22 age- and sex-comparable healthy controls underwent serum MCP-1 measurement and transthoracic echocardiography. Psoriasis Area and Severity Index (PASI), Disease Activity Index for Psoriatic Arthritis (DAPSA), and Axial Spondyloarthritis Disease Activity Score (ASDAS) were assessed as applicable. Results. Patients with PsA had a higher frequency of right- and left-ventricular diastolic dysfunction than controls. Absolute ventricular longitudinal strain was reduced (values were less negative) in the PsA group. No statistically significant association was detected between MCP-1 and ventricular diastolic dysfunction, disease-activity indices, treatment category, inflammatory markers, cardiac biomarkers, or lipid measurements in the analyses presented. The ROC analysis assessed the ability of MCP-1 to discriminate between PsA cases and controls, not to predict cardiac outcomes, and showed limited discriminatory performance (AUC = 0.641; p = 0.067; 95% CI: 0.507–0.761; cutoff >58.7 ng/L; sensitivity 52.63%; specificity 63.64%). Conclusions. In this small exploratory case-control study, the PsA group showed more frequent echocardiographic abnormalities than controls. Serum MCP-1 did not demonstrate a clearly established association with those abnormalities. Longitudinal studies with adequate adjustment for cardiometabolic confounding are required before prognostic or predictive conclusions can be drawn.
Background. Mean platelet volume (MPV) is routinely reported in the complete blood count; however, its role in determining disease activity in systemic lupus erythematosus (SLE) remains unclear. Objectives. To explore the association between MPV and SLE disease activity and to assess whether MPV can distinguish active from inactive disease in comparison with anti-double-stranded DNA (anti-dsDNA) antibodies. Methods. A total of 100 patients with SLE (54 with active and 46 with inactive disease) and 40 healthy controls were enrolled in this cross-sectional study. The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was used to evaluate disease activity. MPV, erythrocyte sedimentation rate (ESR), complement C3 and C4, and anti-dsDNA levels were assessed. Correlation analysis was used to assess associations between laboratory parameters and disease activity. Receiver operating characteristic (ROC) analysis was used to assess the ability of MPV and anti-dsDNA to distinguish active from inactive SLE. Results. Mean MPV was lower in patients with SLE than in healthy controls (8.15 ± 1.45 vs. 9.85 ± 1.12 fL, p < 0.001). Patients with active SLE exhibited lower MPV, C3, and C4 levels and higher anti-dsDNA and ESR levels compared with patients with inactive SLE. MPV was inversely correlated with SLEDAI (r = −0.82, p < 0.001) and anti-dsDNA (r = −0.58, p < 0.001), whereas anti-dsDNA showed a positive correlation with SLEDAI (r = 0.68, p < 0.001). The area under the curve (AUC) was 0.78 for MPV and 0.89 for anti-dsDNA. Conclusions. Higher disease activity in patients with SLE was associated with lower MPV. MPV was less discriminative than anti-dsDNA in distinguishing between active and inactive disease, but it is readily available and could be a valuable addition to the parameters used to assess disease activity.
Objectives. Cartilage oligomeric matrix protein (COMP), a noncollagenous glycoprotein of cartilage, is also present in the vascular extracellular matrix and atherosclerotic plaques. This study aimed to measure serum COMP concentrations in patients with primary knee osteoarthritis (OA) and assess their relationship with disease severity and subclinical vascular involvement. Materials and methods. This cross-sectional study included 60 patients with primary knee OA, contributing 74 knee assessments, and 30 demographically comparable healthy controls. Pain severity was assessed using the visual analog scale (VAS), and physical function using the WOMAC Osteoarthritis Index. Structural severity was evaluated by Kellgren-Lawrence (KL) radiographic grading and OMERACT musculoskeletal ultrasound scoring. Carotid intima-media thickness (CIMT) was measured ultrasonographically at three bilateral anatomical sites, with CIMT ≥0.9 mm considered pathological. Serum COMP concentrations and lipid profiles were also assessed. Results. Patients with knee OA had significantly higher serum COMP levels than controls (2,441.2 ± 1,533.08 vs. 831.3 ± 127.77 pg/mL, p < 0.001). Pathological CIMT thickening was identified in 70% of OA patients. Serum COMP showed a strong positive correlation with CIMT (rs = 0.779, p < 0.001), and both COMP and CIMT were significantly associated with OA severity. Sensitivity analysis showed that the COMP-CIMT correlation remained materially unchanged when the analysis was restricted to one knee per patient. Conclusions. Serum COMP levels were significantly elevated in patients with knee OA and were associated with disease severity. A high burden of subclinical vascular disease was also observed, with a strong positive association between COMP and CIMT. These findings support further investigation of COMP as a potential biomarker linking structural OA severity and subclinical vascular involvement.